Evaluation of Multisensor Data in Heart Failure Patients With Implanted Devices

Brief Summary

Official Title: “Multisensor Chronic Evaluations in Ambulatory Heart Failure Patients”

The goal of the MultiSENSE study is to collect chronic information from multiple sensors in an implanted device for evaluation in heart failure patients.

  • Study Type: Observational
  • Study Design: Observational Model: Case-Only, Time Perspective: Prospective
  • Study Primary Completion Date: August 2014

Detailed Clinical Trial Description

The purpose of MultiSENSE study is to collect data about patient events during worsening heart failure, determine how sensor measurements vary during patient daily activities and during the development and recovery from events of worsening heart failure, develop algorithms capable of detecting the onset of worsening heart failure prior to the overt presentation of patient symptoms using reference measurements: thoracic impedance, heart sounds, physiologic responses to activities and respiration.

Interventions Used in this Clinical Trial

  • Device: COGNIS CRT-D
    • Patients with existing or newly implanted COGNIS® CRT-D pulse generators (PG)are enrolled in the study. PG is modified by the download of investigational software called Sensor Research Device-1™ (SRD-1). The goal of the SRD-1 system is to collect sensor data without affecting the delivered CRT-D therapy. This is accomplished through the “conversion” of an implanted COGNIS PG into a SRD-1 PG by downloading investigational software. Only a market approved COGNIS model N119/N120/P107/P108 device may be converted to a SRD-1 investigational device. There will be no PG hardware changes resulting from the conversion.

Arms, Groups and Cohorts in this Clinical Trial

  • Patients implanted with a CRT-D (Cardiac Resynch. Therapy)

Outcome Measures for this Clinical Trial

Primary Measures

  • Heart Failure (HF) events
    • Time Frame: 12 Months
      Safety Issue?: No

Criteria for Participation in this Clinical Trial

Inclusion Criteria

  • Age 18 or above, or of legal age to give informed consent specific to state and national law
  • Willing and capable of returning for all follow-up visits and emergency care at the investigational center as medically appropriate
  • Willing to participate in all testing associated with this clinical investigation at an approved clinical investigational center
  • Currently implanted with a COGNIS device (Model N119 or N120, P107, P108)
  • Classified as NYHA Class II, III or IV within the last six months

Exclusion Criteria

  • Inability or refusal to sign the Subject Informed Consent
  • Inability of refusal to comply with the follow-up schedule
  • Documented as pacemaker dependent
  • Unable to rest comfortably in a semi-recumbent position for up to 20 minutes
  • Implanted with active Medtronic Fidelis lead models: 6930, 6931, 6948 or 6949
  • Currently implanted with unipolar RA, RV, or LV leads
  • LV sensitivity programmed to less than 0.7 mV AGC
  • History of appropriate tachycardia therapy (external or implanted) for rates < 165 bpm within 1 week prior to enrollment
  • Device battery status indicates approximate time to explant < 2 years
  • Likely to undergo lead or PG revision during the course of the study as determined by the investigator
  • Receiving regularly scheduled intravenous (IV) inotropic therapy as part of their drug regimen
  • Have received heart or lung transplant
  • Receiving mechanical circulatory support
  • Patients who have been referred or admitted for Hospice care
  • A life expectancy of less than 12 months per physician discretion
  • Enrolled in any concurrent study without Boston Scientific written approval
  • Devices previously converted to the SRD-1 and withdrawn from the study
  • Received a sub-pectoral COGNIS implant prior to February 1, 2011 with a dash number listed in Appendix K of the study protocol
  • Known pregnancy or plan to become pregnant within the course of the study
  • LV offset is programmed to a value greater than zero

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial: No

Clinical Trial Investigator Information

  • Lead Sponsor
    • Boston Scientific Corporation
  • Collaborator
    • Milton S. Hershey Medical Center
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • John P Boehmer, M.D., Principal Investigator, Milton S Hershey Medical Center, Hershey, Pennsylvania, United States


J. P. Boehmer, Q. An, Y. Zhang, A. Shih, Variation in daily median respiratory rate identifies patients at higher risk of worsening HF in 30 days, Heart Rhythm, 2013;10(5):S66

J. P. Boehmer, Q. An, Y. Zhang, A. Shih, Patients with higher standard deviation in daily median respiratory rate are at higher risk of worsening HF in 30 days, Europace, 2013;15(Suppl 2):ii96

J. P. Boehmer, Y. Zhang, K. C. Beck, R. J. Sweeny, Physiologic sensor response to activity level in the MultiSENSE Study, European Journal of Heart Failure, 2013:12 (suppl 1), S194-5

J. Hatlestad, S. Mehta, J. Whelan-Schwartz, R. Shankar and J.P. Boehmer, M.D..Night-time Elevation Angles In MultiSENSE Study Are Related To Symptoms of Orthopnea & Paroxysmal Nocturnal Dyspnea, Journal of Cardiac Failure, Vol. 18 No. 8S, Aug 2012, pp. S8

J. P. Boehmer, V. Averina, P. Thakur, Y. Zhang, R. J. Sweeny, J. Thompson, Device-based sensors in the MultiSENSE Study: a preliminary view, Journal of Cardiac Failure, Vol. 18 No. 8S, Aug 2012, pp. S18

J. P. Boehmer, Y. Zhang, R. J. Sweeny, R. Wariar, Q. An, P. Thakur, V. Averina, J. Thompson, Quantifying circadian variation of multiple physiologic signals in ambulatory heart failure patients, Journal of Cardiac Failure, Vol. 18 No. 8S, Aug 2012, pp. S90

J. P. Boehmer, Y. Zhang, K. C. Beck, R. J. Sweeny, Physiologic sensor response to activity level in the MultiSENSE Study, Journal of Cardiac Failure, Vol. 17 No. 8S, Aug 2011, pp. S105


Clinical Trials content is provided directly by the US National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of information about a specific clinical trial contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is: